collegium
announces
five
posters
presented
painweek
national
conference
stoughton
globe
newswire
collegium
pharmaceutical
nasdaq
coll
specialty
pharmaceutical
company
committed
leader
responsible
pain
management
today
announced
five
poster
presentations
highlighting
data
regarding
product
portfolio
presented
annual
painweek
national
conference
took
place
virtually
september
pursuant
collegium
commitment
leading
science
pleased
support
five
posters
regarding
product
portfolio
presented
painweek
past
weekend
said
richard
malamut
executive
vice
president
chief
medical
officer
collegium
year
virtual
scientific
program
provided
timely
opportunity
share
encouraging
data
around
certain
evidence
related
abuse
misuse
diversion
product
poster
presentations
er
oxycodone
tablets
cii
er
tapentadol
tablets
cii
tapentadol
tablets
cii
abused
misused
carry
risk
addiction
products
intended
use
appropriate
pain
patients
treatment
alternatives
inadequate
use
er
er
result
serious
fatal
respiratory
depression
even
used
exactly
prescribed
see
important
safety
information
including
boxed
warning
addiction
abuse
misuse
serious
risks
regarding
three
products
end
press
release
information
painweek
visit
https
collegium
pharmaceutical
collegium
specialty
pharmaceutical
company
committed
leader
responsible
pain
management
collegium
headquarters
located
stoughton
massachusetts
information
please
visit
company
website
er
er
collegium
first
product
utilizing
deterx
technology
platform
xtampza
er
oral
formulation
oxycodone
approved
fda
management
pain
severe
enough
require
daily
opioid
treatment
alternative
treatment
options
inadequate
indications
usage
er
oxycodone
indicated
management
pain
severe
enough
require
daily
opioid
treatment
alternative
treatment
options
inadequate
limitations
use
risks
addiction
abuse
misuse
opioids
even
recommended
doses
greater
risks
overdose
death
opioid
formulations
reserve
xtampza
er
use
patients
alternative
treatment
options
eg
analgesics
opioids
ineffective
tolerated
would
otherwise
inadequate
provide
sufficient
management
pain
xtampza
er
indicated
prn
analgesic
important
safety
information
warning
addiction
abuse
misuse
risk
evaluation
mitigation
strategy
rems
respiratory
depression
accidental
ingestion
neonatal
opioid
withdrawal
syndrome
cytochrome
interaction
risks
concomitant
use
benzodiazepines
cns
depressants
addiction
abuse
misuse
xtampza
er
exposes
patients
users
risks
opioid
addiction
abuse
misuse
lead
overdose
death
assess
patient
risk
prior
prescribing
xtampza
er
monitor
patients
regularly
development
behaviors
conditions
opioid
analgesic
risk
evaluation
mitigation
strategy
rems
ensure
benefits
opioid
analgesics
outweigh
risks
addiction
abuse
misuse
food
drug
administration
fda
required
rems
products
requirements
rems
drug
companies
approved
opioid
analgesic
products
must
make
education
programs
available
healthcare
providers
healthcare
providers
strongly
encouraged
complete
education
program
counsel
patients
caregivers
every
prescription
safe
use
serious
risks
storage
disposal
products
emphasize
patients
caregivers
importance
reading
medication
guide
every
time
provided
pharmacist
consider
tools
improve
patient
household
community
safety
respiratory
depression
serious
fatal
respiratory
depression
may
occur
use
xtampza
er
monitor
respiratory
depression
especially
initiation
xtampza
er
following
dose
increase
accidental
ingestion
accidental
ingestion
even
one
dose
xtampza
er
especially
children
result
fatal
overdose
oxycodone
neonatal
opioid
withdrawal
syndrome
prolonged
use
xtampza
er
pregnancy
result
neonatal
opioid
withdrawal
syndrome
may
recognized
treated
requires
management
according
protocols
developed
neonatology
experts
opioid
use
required
prolonged
period
pregnant
woman
advise
patient
risk
neonatal
opioid
withdrawal
syndrome
ensure
appropriate
treatment
available
cytochrome
interaction
concomitant
use
xtampza
er
cytochrome
inhibitors
may
result
increase
oxycodone
plasma
concentrations
could
increase
prolong
adverse
drug
effects
may
cause
potentially
fatal
respiratory
depression
addition
discontinuation
concomitantly
used
cytochrome
inducer
may
result
increase
oxycodone
plasma
concentration
monitor
patients
receiving
xtampza
er
inhibitor
inducer
risks
concomitant
use
benzodiazepines
cns
depressants
concomitant
use
opioids
benzodiazepines
central
nervous
system
cns
depressants
including
alcohol
may
result
profound
sedation
respiratory
depression
coma
death
reserve
concomitant
prescribing
xtampza
er
benzodiazepines
cns
depressants
use
patients
alternative
treatment
options
inadequate
limit
dosages
durations
minimum
required
follow
patients
signs
symptoms
respiratory
depression
sedation
contraindications
xtampza
er
contraindicated
patients
significant
respiratory
depression
acute
severe
bronchial
asthma
unmonitored
setting
absence
resuscitative
equipment
known
suspected
gastrointestinal
obstruction
including
paralytic
ileus
hypersensitivity
eg
anaphylaxis
oxycodone
warnings
precautions
addiction
abuse
misuse
xtampza
er
contains
oxycodone
schedule
ii
controlled
substance
opioid
xtampza
er
exposes
users
risks
addiction
abuse
misuse
products
xtampza
er
deliver
opioid
extended
period
time
greater
risk
overdose
death
due
larger
amount
oxycodone
present
opioid
analgesic
risk
evaluation
mitigation
strategy
rems
ensure
benefits
opioid
analgesics
outweigh
risks
addiction
abuse
misuse
food
drug
administration
fda
required
risk
evaluation
mitigation
strategy
rems
products
requirements
rems
drug
companies
approved
opioid
analgesic
products
must
make
education
programs
available
healthcare
providers
healthcare
providers
strongly
encouraged
following
complete
education
program
offered
accredited
provider
continuing
education
ce
another
education
program
includes
elements
fda
education
blueprint
health
care
providers
involved
management
support
patients
pain
offered
accredited
provider
continuing
education
ce
another
education
program
includes
elements
fda
education
blueprint
health
care
providers
involved
management
support
patients
pain
discuss
patients
caregivers
every
prescription
safe
use
serious
risks
proper
storage
disposal
products
patient
counseling
guide
pcg
obtained
link
opioidanalgesicremspcg
emphasize
patients
caregivers
importance
reading
medication
guide
every
time
provided
pharmacist
consider
tools
improve
patient
household
community
safety
agreements
reinforce
responsibilities
information
rems
list
accredited
rems
cme
ce
call
visit
fda
blueprint
found
opioidanalgesicremsblueprint
respiratory
depression
serious
fatal
respiratory
depression
reported
use
opioids
even
used
recommended
respiratory
depression
immediately
recognized
treated
may
lead
respiratory
arrest
death
management
respiratory
depression
may
include
close
observation
supportive
measures
use
opioid
antagonists
depending
patient
clinical
status
carbon
dioxide
co
retention
respiratory
depression
exacerbate
sedating
effects
opioids
retention
respiratory
depression
exacerbate
sedating
effects
opioids
opioids
cause
breathing
disorders
including
central
sleep
apnea
csa
hypoxemia
opioid
use
increases
risk
csa
fashion
patients
present
csa
consider
decreasing
opioid
dosage
using
best
practices
opioid
taper
neonatal
opioid
withdrawal
syndrome
prolonged
use
xtampza
er
pregnancy
result
withdrawal
neonate
neonatal
opioid
withdrawal
syndrome
unlike
opioid
withdrawal
syndrome
adults
may
recognized
treated
requires
management
according
protocols
developed
neonatology
experts
observe
newborns
signs
neonatal
opioid
withdrawal
syndrome
manage
accordingly
advise
pregnant
women
using
opioids
prolonged
period
risk
neonatal
opioid
withdrawal
syndrome
ensure
appropriate
treatment
available
risks
concomitant
use
discontinuation
cytochrome
inhibitors
inducers
concomitant
use
xtampza
er
inhibitor
macrolide
antibiotics
eg
erythromycin
agents
eg
ketoconazole
protease
inhibitors
eg
ritonavir
may
increase
plasma
concentrations
oxycodone
prolong
opioid
adverse
reactions
may
cause
potentially
fatal
respiratory
depression
particularly
inhibitor
added
stable
dose
xtampza
er
achieved
similarly
discontinuation
inducer
rifampin
carbamazepine
phenytoin
xtampza
patients
may
increase
oxycodone
plasma
concentrations
prolong
opioid
adverse
reactions
using
xtampza
er
inhibitors
discontinuing
inducers
xtampza
patients
monitor
patients
closely
frequent
intervals
consider
dosage
reduction
xtampza
er
stable
drug
effects
achieved
concomitant
use
xtampza
er
inducers
discontinuation
inhibitor
could
decrease
oxycodone
plasma
concentrations
decrease
opioid
efficacy
possibly
lead
withdrawal
syndrome
patient
developed
physical
dependence
oxycodone
using
xtampza
er
inducers
discontinuing
inhibitors
monitor
patients
closely
frequent
intervals
consider
increasing
opioid
dosage
needed
maintain
adequate
analgesia
symptoms
opioid
withdrawal
occur
risks
concomitant
use
benzodiazepines
cns
depressants
profound
sedation
respiratory
depression
coma
death
may
result
concomitant
use
xtampza
er
benzodiazepines
cns
depressants
eg
sedatives
hypnotics
anxiolytics
tranquilizers
muscle
relaxants
general
anesthetics
antipsychotics
opioids
alcohol
risks
reserve
concomitant
prescribing
drugs
use
patients
alternative
treatment
options
inadequate
observational
studies
demonstrated
concomitant
use
opioid
analgesics
benzodiazepines
increases
risk
mortality
compared
use
opioid
analgesics
alone
similar
pharmacological
properties
reasonable
expect
similar
risk
concomitant
use
cns
depressant
drugs
opioid
analgesics
risk
respiratory
depression
patients
chronic
pulmonary
disease
elderly
cachectic
debilitated
patients
use
xtampza
er
patients
acute
severe
bronchial
asthma
unmonitored
setting
absence
resuscitative
equipment
contraindicated
patients
chronic
pulmonary
disease
xtampza
patients
significant
chronic
obstructive
pulmonary
disease
cor
pulmonale
substantially
decreased
respiratory
reserve
hypoxia
hypercapnia
respiratory
depression
increased
risk
decreased
respiratory
drive
including
apnea
even
recommended
dosages
xtampza
er
elderly
cachectic
debilitated
patients
respiratory
depression
likely
occur
elderly
cachectic
debilitated
patients
may
altered
pharmacokinetics
altered
clearance
compared
younger
healthier
patients
monitor
patients
closely
particularly
initiating
titrating
xtampza
er
xtampza
er
given
concomitantly
drugs
depress
respiration
alternatively
consider
use
analgesics
patients
use
alternative
analgesic
patients
require
dose
xtampza
er
less
adrenal
insufficiency
cases
adrenal
insufficiency
reported
opioid
use
often
following
greater
one
month
use
presentation
adrenal
insufficiency
may
include
symptoms
signs
including
nausea
vomiting
anorexia
fatigue
weakness
dizziness
low
blood
pressure
adrenal
insufficiency
suspected
confirm
diagnosis
diagnostic
testing
soon
possible
adrenal
insufficiency
diagnosed
treat
physiologic
replacement
doses
corticosteroids
wean
patient
opioid
allow
adrenal
function
recover
continue
corticosteroid
treatment
adrenal
function
recovers
opioids
may
tried
cases
reported
use
different
opioid
without
recurrence
adrenal
insufficiency
information
available
identify
particular
opioids
likely
associated
adrenal
insufficiency
severe
hypotension
xtampza
er
may
cause
severe
hypotension
including
orthostatic
hypotension
syncope
ambulatory
patients
increased
risk
patients
whose
ability
maintain
blood
pressure
already
compromised
reduced
blood
volume
concurrent
administration
certain
cns
depressant
drugs
eg
phenothiazines
general
anesthetics
monitor
patients
signs
hypotension
initiating
titrating
dosage
xtampza
er
patients
circulatory
shock
xtampza
er
may
cause
vasodilation
reduce
cardiac
output
blood
pressure
avoid
use
xtampza
er
patients
circulatory
shock
risks
use
patients
increased
intracranial
pressure
brain
tumors
head
injury
impaired
consciousness
patients
may
susceptible
intracranial
effects
co
retention
eg
evidence
increased
intracranial
pressure
brain
tumors
xtampza
er
may
reduce
respiratory
drive
resultant
co
retention
increase
intracranial
pressure
monitor
patients
signs
sedation
respiratory
depression
particularly
initiating
therapy
xtampza
er
retention
eg
evidence
increased
intracranial
pressure
brain
tumors
xtampza
er
may
reduce
respiratory
drive
resultant
co
retention
increase
intracranial
pressure
monitor
patients
signs
sedation
respiratory
depression
particularly
initiating
therapy
xtampza
er
opioids
may
also
obscure
clinical
course
patient
head
injury
avoid
use
xtampza
er
patients
impaired
consciousness
coma
risks
use
patients
gastrointestinal
conditions
xtampza
er
contraindicated
patients
gastrointestinal
obstruction
including
paralytic
ileus
oxycodone
xtampza
er
may
cause
spasm
sphincter
oddi
opioids
may
cause
increases
serum
amylase
monitor
patients
biliary
tract
disease
including
acute
pancreatitis
worsening
symptoms
risk
use
patients
seizure
disorders
oxycodone
xtampza
er
may
increase
frequency
seizures
patients
seizure
disorders
may
increase
risk
seizures
clinical
settings
associated
seizures
monitor
patients
history
seizure
disorders
worsened
seizure
control
xtampza
er
therapy
withdrawal
abruptly
discontinue
xtampza
er
patient
physically
dependent
opioids
discontinuing
xtampza
er
physically
dependent
patient
gradually
taper
dosage
rapid
tapering
oxycodone
patient
physically
dependent
opioids
may
lead
withdrawal
syndrome
return
pain
additionally
avoid
use
mixed
agonist
antagonist
eg
pentazocine
nalbuphine
butorphanol
partial
agonist
eg
buprenorphine
analgesics
patients
received
receiving
course
therapy
full
opioid
agonist
analgesic
including
xtampza
er
patients
mixed
agonist
antagonist
partial
agonist
analgesics
may
reduce
analgesic
effect
may
precipitate
withdrawal
symptoms
risks
driving
operating
machinery
xtampza
er
may
impair
mental
physical
abilities
needed
perform
potentially
hazardous
activities
driving
car
operating
machinery
warn
patients
drive
operate
dangerous
machinery
unless
tolerant
effects
xtampza
er
know
react
medication
laboratory
monitoring
every
urine
drug
test
opioids
opiates
detects
oxycodone
reliably
especially
designed
use
many
laboratories
report
urine
drug
concentrations
specified
value
therefore
urine
testing
oxycodone
considered
clinical
management
individual
patient
ensure
sensitivity
specificity
assay
appropriate
consider
limitations
testing
used
interpreting
results
administration
food
instruct
patients
always
take
xtampza
er
capsules
food
approximately
amount
food
order
ensure
consistent
plasma
levels
achieved
patients
difficulty
swallowing
xtampza
er
also
taken
sprinkle
soft
foods
sprinkled
cup
administered
directly
mouth
nasogastric
gastric
feeding
tube
adverse
reactions
common
adverse
reactions
reported
patients
phase
clinical
trial
comparing
xtampza
er
placebo
nausea
headache
constipation
somnolence
pruritus
vomiting
dizziness
please
see
full
prescribing
information
including
boxed
warning
er
tapentadol
indications
usage
nucynta
er
tapentadol
indicated
management
pain
severe
enough
require
daily
opioid
treatment
alternative
treatment
options
inadequate
neuropathic
pain
associated
diabetic
peripheral
neuropathy
dpn
severe
enough
require
daily
term
opioid
treatment
alternative
treatment
options
inadequate
limitations
use
risks
addiction
abuse
misuse
opioids
even
recommended
doses
greater
risks
overdose
death
opioid
formulations
reserve
nucynta
er
use
patients
alternative
treatment
options
eg
analgesics
opioids
ineffective
tolerated
would
otherwise
inadequate
provide
sufficient
management
pain
nucynta
er
indicated
prn
analgesic
warning
addiction
abuse
misuse
risk
evaluation
mitigation
strategy
rems
respiratory
depression
accidental
ingestion
neonatal
opioid
withdrawal
syndrome
interaction
alcohol
risks
concomitant
use
benzodiazepines
cns
depressants
addiction
abuse
misuse
nucynta
er
exposes
patients
users
risks
opioid
addiction
abuse
misuse
lead
overdose
death
assess
patient
risk
prior
prescribing
nucynta
er
monitor
patients
regularly
development
behaviors
conditions
opioid
analgesic
risk
evaluation
mitigation
strategy
rems
ensure
benefits
opioid
analgesics
outweigh
risks
addiction
abuse
misuse
food
drug
administration
fda
required
rems
products
requirements
rems
drug
companies
approved
opioid
analgesic
products
must
make
education
programs
available
healthcare
providers
healthcare
providers
strongly
encouraged
complete
education
program
counsel
patients
caregivers
every
prescription
safe
use
serious
risks
storage
disposal
products
emphasize
patients
caregivers
importance
reading
medication
guide
every
time
provided
pharmacist
consider
tools
improve
patient
household
community
safety
respiratory
depression
serious
fatal
respiratory
depression
may
occur
use
nucynta
er
monitor
respiratory
depression
especially
initiation
nucynta
er
following
dose
increase
instruct
patients
swallow
nucynta
er
tablets
whole
crushing
chewing
dissolving
nucynta
er
tablets
cause
rapid
release
absorption
potentially
fatal
dose
tapentadol
accidental
ingestion
accidental
ingestion
even
one
dose
nucynta
er
especially
children
result
fatal
overdose
tapentadol
neonatal
opioid
withdrawal
syndrome
prolonged
use
nucynta
er
pregnancy
result
neonatal
opioid
withdrawal
syndrome
may
threatening
recognized
treated
requires
management
according
protocols
developed
neonatology
experts
opioid
use
required
prolonged
period
pregnant
woman
advise
patient
risk
neonatal
opioid
withdrawal
syndrome
ensure
appropriate
treatment
available
interaction
alcohol
instruct
patients
consume
alcoholic
beverages
use
prescription
products
contain
alcohol
taking
nucynta
er
alcohol
nucynta
er
may
result
increased
plasma
tapentadol
levels
potentially
fatal
overdose
tapentadol
risks
concomitant
use
benzodiazepines
cns
depressants
concomitant
use
opioids
benzodiazepines
central
nervous
system
cns
depressants
including
alcohol
may
result
profound
sedation
respiratory
depression
coma
death
reserve
concomitant
prescribing
nucynta
er
benzodiazepines
cns
depressants
use
patients
alternative
treatment
options
inadequate
limit
dosages
durations
minimum
required
follow
patients
signs
symptoms
respiratory
depression
sedation
contraindications
nucynta
er
contraindicated
patients
significant
respiratory
depression
acute
severe
bronchial
asthma
hypercarbia
unmonitored
setting
absence
resuscitative
equipment
known
suspected
gastrointestinal
obstruction
including
paralytic
ileus
hypersensitivity
eg
anaphylaxis
angioedema
tapentadol
ingredients
product
concurrent
use
monoamine
oxidase
inhibitors
maois
use
maois
within
last
days
warnings
precautions
addiction
abuse
misuse
nucynta
er
contains
tapentadol
schedule
ii
controlled
substance
opioid
nucynta
er
exposes
users
risks
addiction
abuse
misuse
products
nucynta
er
deliver
opioid
extended
period
time
greater
risk
overdose
death
due
larger
amount
tapentadol
present
although
risk
addiction
individual
unknown
occur
patients
appropriately
prescribed
nucynta
er
addiction
occur
recommended
doses
drug
misused
abused
assess
patient
risk
opioid
addiction
abuse
misuse
prior
prescribing
nucynta
er
monitor
patients
receiving
nucynta
er
development
behaviors
conditions
risks
increased
patients
personal
family
history
substance
abuse
including
drug
alcohol
abuse
addiction
mental
illness
eg
major
depression
potential
risks
however
prevent
prescribing
nucynta
er
proper
management
pain
given
patient
patients
increased
risk
may
prescribed
opioids
nucynta
er
use
patients
necessitates
intensive
counseling
risks
proper
use
nucynta
er
along
intensive
monitoring
signs
addiction
abuse
misuse
abuse
misuse
nucynta
er
crushing
chewing
snorting
injecting
dissolved
product
result
uncontrolled
delivery
tapentadol
result
overdose
death
opioids
sought
drug
abusers
people
addiction
disorders
subject
criminal
diversion
consider
risks
prescribing
dispensing
nucynta
er
strategies
reduce
risks
include
prescribing
drug
smallest
appropriate
quantity
advising
patient
proper
disposal
unused
drug
contact
local
state
professional
licensing
board
state
controlled
substances
authority
information
prevent
detect
abuse
diversion
product
opioid
analgesic
risk
evaluation
mitigation
strategy
rems
ensure
benefits
opioid
analgesics
outweigh
risks
addiction
abuse
misuse
food
drug
administration
fda
required
risk
evaluation
mitigation
strategy
rems
products
requirements
rems
drug
companies
approved
opioid
analgesic
products
must
make
education
programs
available
healthcare
providers
healthcare
providers
strongly
encouraged
following
complete
education
program
offered
accredited
provider
continuing
education
ce
another
education
program
includes
elements
fda
education
blueprint
health
care
providers
involved
management
support
patients
pain
offered
accredited
provider
continuing
education
ce
another
education
program
includes
elements
fda
education
blueprint
health
care
providers
involved
management
support
patients
pain
discuss
safe
use
serious
risks
proper
storage
disposal
opioid
analgesics
patients
caregivers
every
time
medicines
prescribed
patient
counseling
guide
pcg
obtained
link
opioidanalgesicremspcg
emphasize
patients
caregivers
importance
reading
medication
guide
receive
pharmacist
every
time
opioid
analgesic
dispensed
consider
using
tools
improve
patient
household
community
safety
agreements
reinforce
responsibilities
obtain
information
opioid
analgesic
rems
list
accredited
rems
cme
ce
call
log
fda
blueprint
found
opioidanalgesicremsblueprint
respiratory
depression
serious
fatal
respiratory
depression
reported
use
opioids
even
used
recommended
respiratory
depression
immediately
recognized
treated
may
lead
respiratory
arrest
death
management
respiratory
depression
may
include
close
observation
supportive
measures
use
opioid
antagonists
depending
patient
clinical
status
carbon
dioxide
co
retention
respiratory
depression
exacerbate
sedating
effects
opioids
serious
fatal
respiratory
depression
occur
time
use
nucynta
er
risk
greatest
initiation
therapy
following
dosage
increase
monitor
patients
closely
respiratory
depression
especially
within
first
hours
initiating
therapy
following
dosage
increases
nucynta
er
reduce
risk
respiratory
depression
proper
dosing
titration
nucynta
er
essential
overestimating
nucynta
er
dosage
converting
patients
another
opioid
product
result
fatal
overdose
first
dose
accidental
ingestion
even
one
dose
nucynta
er
especially
children
result
respiratory
depression
death
due
overdose
tapentadol
opioids
cause
breathing
disorders
including
central
sleep
apnea
csa
hypoxemia
opioid
use
increases
risk
csa
fashion
patients
present
csa
consider
decreasing
opioid
dosage
using
best
practices
opioid
taper
neonatal
opioid
withdrawal
syndrome
prolonged
use
nucynta
er
pregnancy
result
withdrawal
neonate
neonatal
opioid
withdrawal
syndrome
unlike
opioid
withdrawal
syndrome
adults
may
recognized
treated
requires
management
according
protocols
developed
neonatology
experts
observe
newborns
signs
neonatal
opioid
withdrawal
syndrome
manage
accordingly
advise
pregnant
women
using
opioids
prolonged
period
risk
neonatal
opioid
withdrawal
syndrome
ensure
appropriate
treatment
available
risk
concomitant
use
benzodiazepines
cns
depressants
patients
must
consume
alcoholic
beverages
prescription
products
containing
alcohol
nucynta
er
therapy
alcohol
nucynta
er
may
result
increased
plasma
tapentadol
levels
potentially
fatal
overdose
tapentadol
profound
sedation
respiratory
depression
coma
death
may
result
concomitant
use
nucynta
er
benzodiazepines
cns
depressants
eg
sedatives
hypnotics
anxiolytics
tranquilizers
muscle
relaxants
general
anesthetics
antipsychotics
opioids
alcohol
risks
reserve
concomitant
prescribing
drugs
use
patients
alternative
treatment
options
inadequate
observational
studies
demonstrated
concomitant
use
opioid
analgesics
benzodiazepines
increases
risk
mortality
compared
use
opioid
analgesics
alone
similar
pharmacological
properties
reasonable
expect
similar
risk
concomitant
use
cns
depressant
drugs
opioid
analgesics
decision
made
prescribe
benzodiazepine
cns
depressant
concomitantly
opioid
analgesic
prescribe
lowest
effective
dosages
minimum
durations
concomitant
use
patients
already
receiving
opioid
analgesic
prescribe
lower
initial
dose
benzodiazepine
cns
depressant
indicated
absence
opioid
titrate
based
clinical
response
opioid
analgesic
initiated
patient
already
taking
benzodiazepine
cns
depressant
prescribe
lower
initial
dose
opioid
analgesic
titrate
based
clinical
response
follow
patients
closely
signs
symptoms
respiratory
depression
sedation
advise
patients
caregivers
risks
respiratory
depression
sedation
nucynta
er
used
benzodiazepines
cns
depressants
including
alcohol
illicit
drugs
advise
patients
drive
operate
heavy
machinery
effects
concomitant
use
benzodiazepine
cns
depressants
determined
screen
patients
risk
substance
use
disorders
including
opioid
abuse
misuse
warn
risk
overdose
death
associated
use
additional
cns
depressants
including
alcohol
illicit
drugs
risk
respiratory
depression
patients
chronic
pulmonary
disease
elderly
cachectic
debilitated
patients
use
nucynta
er
patients
acute
severe
bronchial
asthma
unmonitored
setting
absence
resuscitative
equipment
contraindicated
patients
chronic
pulmonary
disease
nucynta
patients
significant
chronic
obstructive
pulmonary
disease
cor
pulmonale
substantially
decreased
respiratory
reserve
hypoxia
hypercapnia
respiratory
depression
increased
risk
decreased
respiratory
drive
including
apnea
even
recommended
dosages
nucynta
er
elderly
cachectic
debilitated
patients
respiratory
depression
likely
occur
elderly
cachectic
debilitated
patients
may
altered
pharmacokinetics
altered
clearance
compared
younger
healthier
patients
alternatively
consider
use
analgesics
patients
monitor
patients
closely
particularly
initiating
titrating
nucynta
er
nucynta
er
given
concomitantly
drugs
depress
respiration
serotonin
syndrome
concomitant
use
serotonergic
drugs
cases
serotonin
syndrome
potentially
condition
reported
concomitant
use
tapentadol
serotonergic
drugs
serotonergic
drugs
include
selective
serotonin
reuptake
inhibitors
ssris
serotonin
norepinephrine
reuptake
inhibitors
snris
tricyclic
antidepressants
tcas
triptans
receptor
antagonists
drugs
affect
serotonergic
neurotransmitter
system
eg
mirtazapine
trazodone
tramadol
certain
muscle
relaxants
ie
cyclobenzaprine
metaxalone
drugs
impair
metabolism
serotonin
including
mao
inhibitors
intended
treat
psychiatric
disorders
also
others
linezolid
intravenous
methylene
blue
may
occur
within
recommended
dosage
range
serotonin
syndrome
symptoms
may
include
mental
status
changes
eg
agitation
hallucinations
coma
autonomic
instability
eg
tachycardia
labile
blood
pressure
hyperthermia
neuromuscular
aberrations
eg
hyperreflexia
incoordination
rigidity
gastrointestinal
symptoms
eg
nausea
vomiting
diarrhea
onset
symptoms
generally
occurs
within
several
hours
days
concomitant
use
may
occur
later
discontinue
nucynta
er
serotonin
syndrome
suspected
adrenal
insufficiency
cases
adrenal
insufficiency
reported
opioid
use
often
following
greater
one
month
use
presentation
adrenal
insufficiency
may
include
symptoms
signs
including
nausea
vomiting
anorexia
fatigue
weakness
dizziness
low
blood
pressure
adrenal
insufficiency
suspected
confirm
diagnosis
diagnostic
testing
soon
possible
adrenal
insufficiency
diagnosed
treat
physiologic
replacement
doses
corticosteroids
wean
patient
opioid
allow
adrenal
function
recover
continue
corticosteroid
treatment
adrenal
function
recovers
opioids
may
tried
cases
reported
use
different
opioid
without
recurrence
adrenal
insufficiency
information
available
identify
particular
opioids
likely
associated
adrenal
insufficiency
severe
hypotension
nucynta
er
may
cause
severe
hypotension
including
orthostatic
hypotension
syncope
ambulatory
patients
increased
risk
patients
whose
ability
maintain
blood
pressure
already
compromised
reduced
blood
volume
concurrent
administration
certain
cns
depressant
drugs
eg
phenothiazines
general
anesthetics
monitor
patients
signs
hypotension
initiating
titrating
dosage
nucynta
er
patients
circulatory
shock
nucynta
er
may
cause
vasodilation
reduce
cardiac
output
blood
pressure
avoid
use
nucynta
er
patients
circulatory
shock
risks
use
patients
increased
intracranial
pressure
brain
tumors
head
injury
impaired
consciousness
patients
may
susceptible
intracranial
effects
co
retention
eg
evidence
increased
intracranial
pressure
brain
tumors
nucynta
er
may
reduce
respiratory
drive
resultant
co
retention
increase
intracranial
pressure
monitor
patients
signs
sedation
respiratory
depression
particularly
initiating
therapy
nucynta
er
opioids
may
also
obscure
clinical
course
patient
head
injury
avoid
use
nucynta
er
patients
impaired
consciousness
coma
risks
use
patients
gastrointestinal
conditions
nucynta
er
contraindicated
patients
known
suspected
gastrointestinal
obstruction
including
paralytic
ileus
tapentadol
nucynta
er
may
cause
spasm
sphincter
oddi
opioids
may
cause
increases
serum
amylase
monitor
patients
biliary
tract
disease
including
acute
pancreatitis
worsening
symptoms
increased
risk
seizures
patients
seizure
disorders
tapentadol
nucynta
er
may
increase
frequency
seizures
patients
seizure
disorders
may
increase
risk
seizures
clinical
settings
associated
seizures
monitor
patients
history
seizure
disorders
worsened
seizure
control
nucynta
er
therapy
withdrawal
abruptly
discontinue
nucynta
er
patient
physically
dependent
opioids
discontinuing
nucynta
er
physically
dependent
patient
gradually
taper
dosage
rapid
tapering
tapentadol
patient
physically
dependent
opioids
may
lead
withdrawal
syndrome
return
pain
additionally
avoid
use
mixed
agonist
antagonist
eg
pentazocine
nalbuphine
butorphanol
partial
agonist
eg
buprenorphine
analgesics
patients
received
receiving
course
therapy
full
opioid
agonist
analgesic
including
nucynta
er
patients
mixed
agonists
antagonists
partial
agonist
analgesics
may
reduce
analgesic
effect
may
precipitate
withdrawal
symptoms
risks
driving
operating
machinery
nucynta
er
may
impair
mental
physical
abilities
needed
perform
potentially
hazardous
activities
driving
car
operating
machinery
warn
patients
drive
operate
dangerous
machinery
unless
tolerant
effects
nucynta
er
know
react
medication
risk
toxicity
patients
hepatic
impairment
study
formulation
tapentadol
subjects
hepatic
impairment
showed
higher
serum
concentrations
tapentadol
normal
hepatic
function
avoid
use
nucynta
er
patients
severe
hepatic
impairment
reduce
dose
nucynta
er
patients
moderate
hepatic
impairment
closely
monitor
patients
moderate
hepatic
impairment
respiratory
central
nervous
system
depression
initiating
titrating
nucynta
er
risk
toxicity
patients
renal
impairment
use
nucynta
er
patients
severe
renal
impairment
recommended
due
accumulation
metabolite
formed
glucuronidation
tapentadol
clinical
relevance
elevated
metabolite
known
adverse
reactions
clinical
studies
common
adverse
reactions
nausea
constipation
dizziness
headache
somnolence
please
see
full
prescribing
information
including
boxed
warning
tapentadol
indications
usage
nucynta
tapentadol
tablets
indicated
management
acute
pain
severe
enough
require
opioid
analgesic
alternative
treatments
inadequate
adults
limitations
use
risks
addiction
abuse
misuse
opioids
even
recommended
doses
reserve
nucynta
tablets
use
patients
alternative
treatment
options
eg
analgesics
opioid
combination
products
tolerated
expected
tolerated
provided
adequate
analgesia
expected
provide
adequate
analgesia
important
safety
information
warning
addiction
abuse
misuse
risk
evaluation
mitigation
strategy
rems
respiratory
depression
accidental
ingestion
neonatal
opioid
withdrawal
syndrome
risks
concomitant
use
benzodiazepines
cns
depressants
addiction
abuse
misuse
nucynta
tablets
expose
patients
users
risks
opioid
addiction
abuse
misuse
lead
overdose
death
assess
patient
risk
prior
prescribing
nucynta
tablets
monitor
patients
regularly
development
behaviors
conditions
opioid
analgesic
risk
evaluation
mitigation
strategy
rems
ensure
benefits
opioid
analgesics
outweigh
risks
addiction
abuse
misuse
food
drug
administration
fda
required
rems
products
requirements
rems
drug
companies
approved
opioid
analgesic
products
must
make
education
programs
available
healthcare
providers
healthcare
providers
strongly
encouraged
complete
education
program
counsel
patients
caregivers
every
prescription
safe
use
serious
risks
storage
disposal
products
emphasize
patients
caregivers
importance
reading
medication
guide
every
time
provided
pharmacist
consider
tools
improve
patient
household
community
safety
respiratory
depression
serious
fatal
respiratory
depression
may
occur
use
nucynta
tablets
monitor
respiratory
depression
especially
initiation
nucynta
tablets
following
dose
increase
accidental
ingestion
accidental
ingestion
even
one
dose
nucynta
tablets
especially
children
result
fatal
overdose
tapentadol
neonatal
opioid
withdrawal
syndrome
prolonged
use
nucynta
tablets
pregnancy
result
neonatal
opioid
withdrawal
syndrome
may
recognized
treated
requires
management
according
protocols
developed
neonatology
experts
opioid
use
required
prolonged
period
pregnant
woman
advise
patient
risk
neonatal
opioid
withdrawal
syndrome
ensure
appropriate
treatment
available
risks
concomitant
use
benzodiazepines
cns
depressants
concomitant
use
opioids
benzodiazepines
central
nervous
system
cns
depressants
including
alcohol
may
result
profound
sedation
respiratory
depression
coma
death
reserve
concomitant
prescribing
nucynta
tablets
benzodiazepines
cns
depressants
use
patients
alternative
treatment
options
inadequate
limit
dosages
durations
minimum
required
follow
patients
signs
symptoms
respiratory
depression
sedation
contraindications
nucynta
tablets
contraindicated
patients
significant
respiratory
depression
acute
severe
bronchial
asthma
unmonitored
setting
absence
resuscitative
equipment
known
suspected
gastrointestinal
obstruction
including
suspected
paralytic
ileus
hypersensitivity
tapentadol
eg
anaphylaxis
angioedema
ingredients
product
concurrent
use
monoamine
oxidase
inhibitors
maois
use
maois
within
last
days
warnings
precautions
addiction
abuse
misuse
nucynta
tablets
contain
tapentadol
schedule
ii
controlled
substance
opioid
nucynta
tablets
expose
users
risks
addiction
abuse
misuse
although
risk
addiction
individual
unknown
occur
patients
appropriately
prescribed
nucynta
tablets
addiction
occur
recommended
dosages
drug
misused
abused
assess
patient
risk
opioid
addiction
abuse
misuse
prior
prescribing
nucynta
tablets
monitor
patients
receiving
nucynta
tablets
development
behaviors
conditions
risks
increased
patients
personal
family
history
substance
abuse
including
drug
alcohol
abuse
addiction
mental
illness
eg
major
depression
potential
risks
however
prevent
proper
management
pain
given
patient
patients
increased
risk
may
prescribed
opioids
nucynta
tablets
use
patients
necessitates
intensive
counseling
risks
proper
use
nucynta
tablets
along
intensive
monitoring
signs
addiction
abuse
misuse
opioids
sought
drug
abusers
people
addiction
disorders
subject
criminal
diversion
consider
risks
prescribing
dispensing
nucynta
tablets
strategies
reduce
risks
include
prescribing
drug
smallest
appropriate
quantity
advising
patient
proper
disposal
unused
drug
contact
local
state
professional
licensing
board
state
controlled
substances
authority
information
prevent
detect
abuse
diversion
product
opioid
analgesic
risk
evaluation
mitigation
strategy
rems
ensure
benefits
opioid
analgesics
outweigh
risks
addiction
abuse
misuse
food
drug
administration
fda
required
risk
evaluation
mitigation
strategy
rems
products
requirements
rems
drug
companies
approved
opioid
analgesic
products
must
make
education
programs
available
healthcare
providers
healthcare
providers
strongly
encouraged
following
complete
education
program
offered
accredited
provider
continuing
education
ce
another
education
program
includes
elements
fda
education
blueprint
health
care
providers
involved
management
support
patients
pain
offered
accredited
provider
continuing
education
ce
another
education
program
includes
elements
fda
education
blueprint
health
care
providers
involved
management
support
patients
pain
discuss
safe
use
serious
risks
proper
storage
disposal
opioid
analgesics
patients
caregivers
every
time
medicines
prescribed
patient
counseling
guide
pcg
obtained
link
opioidanalgesicremspcg
emphasize
patients
caregivers
importance
reading
medication
guide
receive
pharmacist
every
time
opioid
analgesic
dispensed
consider
using
tools
improve
patient
household
community
safety
agreements
reinforce
prescriber
responsibilities
obtain
information
opioid
analgesic
rems
list
accredited
rems
cme
ce
call
log
fda
blueprint
found
opioidanalgesicremsblueprint
respiratory
depression
serious
fatal
respiratory
depression
reported
use
opioids
even
used
recommended
respiratory
depression
immediately
recognized
treated
may
lead
respiratory
arrest
death
management
respiratory
depression
may
include
close
observation
supportive
measures
use
opioid
antagonists
depending
patient
clinical
status
carbon
dioxide
co
retention
respiratory
depression
exacerbate
sedating
effects
opioids
serious
fatal
respiratory
depression
occur
time
use
nucynta
tablets
risk
greatest
initiation
therapy
following
dosage
increase
monitor
patients
closely
respiratory
depression
especially
within
first
hours
initiating
therapy
following
dosage
increases
nucynta
tablets
reduce
risk
respiratory
depression
proper
dosing
titration
nucynta
tablets
essential
overestimating
nucynta
tablets
dosage
converting
patients
another
opioid
product
result
fatal
overdose
first
dose
accidental
ingestion
even
one
dose
nucynta
tablets
especially
children
result
respiratory
depression
death
due
overdose
tapentadol
opioids
cause
breathing
disorders
including
central
sleep
apnea
csa
hypoxemia
opioid
use
increases
risk
csa
fashion
patients
present
csa
consider
decreasing
opioid
dosage
using
best
practices
opioid
taper
neonatal
opioid
withdrawal
syndrome
prolonged
use
nucynta
tablets
pregnancy
result
withdrawal
neonate
neonatal
opioid
withdrawal
syndrome
unlike
opioid
withdrawal
syndrome
adults
may
recognized
treated
requires
management
according
protocols
developed
neonatology
experts
observe
newborns
signs
neonatal
opioid
withdrawal
syndrome
manage
accordingly
advise
pregnant
women
using
opioids
prolonged
period
risk
neonatal
opioid
withdrawal
syndrome
ensure
appropriate
treatment
available
risks
concomitant
use
benzodiazepines
cns
depressants
profound
sedation
respiratory
depression
coma
death
may
result
concomitant
use
nucynta
tablets
benzodiazepines
cns
depressants
eg
sedatives
hypnotics
anxiolytics
tranquilizers
muscle
relaxants
general
anesthetics
antipsychotics
opioids
alcohol
risks
reserve
concomitant
prescribing
drugs
use
patients
alternative
treatment
options
inadequate
observational
studies
demonstrated
concomitant
use
opioid
analgesics
benzodiazepines
increases
risk
mortality
compared
use
opioid
analgesics
alone
similar
pharmacological
properties
reasonable
expect
similar
risk
concomitant
use
cns
depressant
drugs
opioid
analgesics
decision
made
prescribe
benzodiazepine
cns
depressant
concomitantly
opioid
analgesic
prescribe
lowest
effective
dosages
minimum
durations
concomitant
use
patients
already
receiving
opioid
analgesic
prescribe
lower
initial
dose
benzodiazepine
cns
depressant
indicated
absence
opioid
titrate
based
clinical
response
opioid
analgesic
initiated
patient
already
taking
benzodiazepine
cns
depressant
prescribe
lower
initial
dose
opioid
analgesic
titrate
based
clinical
response
follow
patients
closely
signs
symptoms
respiratory
depression
sedation
advise
patients
caregivers
risks
respiratory
depression
sedation
nucynta
tablets
used
benzodiazepines
cns
depressants
including
alcohol
illicit
drugs
advise
patients
drive
operate
heavy
machinery
effects
concomitant
use
benzodiazepine
cns
depressant
determined
screen
patients
risk
substance
use
disorders
including
opioid
abuse
misuse
warn
risk
overdose
death
associated
use
additional
cns
depressants
including
alcohol
illicit
drugs
respiratory
depression
patients
chronic
pulmonary
disease
elderly
cachectic
debilitated
patients
use
nucynta
tablets
patients
acute
severe
bronchial
asthma
unmonitored
setting
absence
resuscitative
equipment
contraindicated
patients
chronic
pulmonary
disease
nucynta
patients
significant
chronic
obstructive
pulmonary
disease
cor
pulmonale
substantially
decreased
respiratory
reserve
hypoxia
hypercapnia
respiratory
depression
increased
risk
decreased
respiratory
drive
including
apnea
even
recommended
dosages
nucynta
tablets
elderly
cachectic
debilitated
patients
respiratory
depression
likely
occur
elderly
cachectic
debilitated
patients
may
altered
pharmacokinetics
altered
clearance
compared
younger
healthier
patients
monitor
patients
closely
particularly
initiating
titrating
nucynta
tablets
nucynta
tablets
given
concomitantly
drugs
depress
respiration
alternatively
consider
use
analgesics
patients
serotonin
syndrome
concomitant
use
serotonergic
drugs
cases
serotonin
syndrome
potentially
condition
reported
concurrent
use
tapentadol
serotonergic
drugs
serotonergic
drugs
include
selective
serotonin
reuptake
inhibitors
ssris
serotonin
norepinephrine
reuptake
inhibitors
snris
tricyclic
antidepressants
tcas
triptans
receptor
antagonists
drugs
affect
serotonergic
neurotransmitter
system
eg
mirtazapine
trazodone
tramadol
certain
muscle
relaxants
ie
cyclobenzaprine
metaxalone
drugs
impair
metabolism
serotonin
including
mao
inhibitors
intended
treat
psychiatric
disorders
also
others
linezolid
intravenous
methylene
blue
may
occur
within
recommended
dosage
range
serotonin
syndrome
symptoms
may
include
changes
eg
agitation
hallucinations
coma
autonomic
instability
eg
tachycardia
labile
blood
pressure
hyperthermia
neuromuscular
aberrations
eg
hyperreflexia
incoordination
gastrointestinal
symptoms
eg
nausea
vomiting
diarrhea
fatal
onset
symptoms
generally
occurs
within
several
hours
days
concomitant
use
may
occur
later
discontinue
nucynta
tablets
serotonin
syndrome
suspected
adrenal
insufficiency
cases
adrenal
insufficiency
reported
opioid
use
often
following
greater
one
month
use
presentation
adrenal
insufficiency
may
include
symptoms
signs
including
nausea
vomiting
anorexia
fatigue
weakness
dizziness
low
blood
pressure
adrenal
insufficiency
suspected
confirm
diagnosis
diagnostic
testing
soon
possible
adrenal
insufficiency
diagnosed
treat
physiologic
replacement
doses
corticosteroids
wean
patient
opioid
allow
adrenal
function
recover
continue
corticosteroid
treatment
adrenal
function
recovers
opioids
may
tried
cases
reported
use
different
opioid
without
recurrence
adrenal
insufficiency
information
available
identify
particular
opioids
likely
associated
adrenal
insufficiency
severe
hypotension
nucynta
tablets
may
cause
severe
hypotension
including
orthostatic
hypotension
syncope
ambulatory
patients
increased
risk
patients
whose
ability
maintain
blood
pressure
already
compromised
reduced
blood
volume
concurrent
administration
certain
cns
depressant
drugs
eg
phenothiazines
general
anesthetics
monitor
patients
signs
hypotension
initiating
titrating
dosage
nucynta
tablets
patients
circulatory
shock
nucynta
tablets
may
cause
vasodilation
reduce
cardiac
output
blood
pressure
avoid
use
nucynta
tablets
patients
circulatory
shock
risks
use
patients
increased
intracranial
pressure
brain
tumors
head
injury
impaired
consciousness
patients
may
susceptible
intracranial
effects
co
retention
eg
evidence
increased
intracranial
pressure
brain
tumors
nucynta
tablets
may
reduce
respiratory
drive
resultant
co
retention
increase
intracranial
pressure
monitor
patients
signs
sedation
respiratory
depression
particularly
initiating
therapy
nucynta
tablets
opioids
may
also
obscure
clinical
course
patient
head
injury
avoid
use
nucynta
tablets
patients
impaired
consciousness
coma
risks
use
patients
gastrointestinal
conditions
nucynta
tablets
contraindicated
patients
known
suspected
gastrointestinal
obstruction
including
paralytic
ileus
tapentadol
nucynta
tablets
may
cause
spasm
sphincter
oddi
opioids
may
cause
increases
serum
amylase
monitor
patients
biliary
tract
disease
including
acute
pancreatitis
worsening
symptoms
increased
risk
seizures
patients
seizure
disorders
tapentadol
nucynta
tablets
may
increase
frequency
seizures
patients
seizure
disorders
may
increase
risk
seizures
occurring
clinical
settings
associated
seizures
monitor
patients
history
seizure
disorders
worsened
seizure
control
nucynta
tablets
therapy
withdrawal
abruptly
discontinue
nucynta
tablets
patient
physically
dependent
opioids
discontinuing
nucynta
tablets
physically
dependent
patient
gradually
taper
dosage
rapid
tapering
tapentadol
patient
physically
dependent
opioids
may
lead
withdrawal
syndrome
return
pain
additionally
avoid
use
mixed
agonist
antagonist
eg
pentazocine
nalbuphine
butorphanol
partial
agonist
eg
buprenorphine
analgesics
patients
receiving
full
opioid
agonist
analgesic
including
nucynta
tablets
patients
mixed
agonist
antagonist
partial
agonist
analgesics
may
reduce
analgesic
effect
precipitate
withdrawal
symptoms
risks
driving
operating
machinery
nucynta
tablets
may
impair
mental
physical
abilities
needed
perform
potentially
hazardous
activities
driving
car
operating
machinery
warn
patients
drive
operate
dangerous
machinery
unless
tolerant
effects
nucynta
tablets
know
react
medication
interactions
alcohol
opioids
drugs
abuse
due
agonist
activity
nucynta
tablets
may
expected
additive
effects
used
conjunction
alcohol
opioids
illicit
drugs
cause
central
nervous
system
depression
respiratory
depression
hypotension
profound
sedation
coma
death
instruct
patients
consume
alcoholic
beverages
use
prescription
products
containing
alcohol
opioids
drugs
abuse
nucynta
tablets
therapy
risk
toxicity
patients
hepatic
impairment
study
nucynta
tablets
subjects
hepatic
impairment
showed
higher
serum
concentrations
tapentadol
normal
hepatic
function
avoid
use
nucynta
tablets
patients
severe
hepatic
impairment
reduce
dose
nucynta
tablets
patients
moderate
hepatic
impairment
closely
monitor
patients
moderate
hepatic
impairment
respiratory
central
nervous
system
depression
receiving
nucynta
tablets
risk
toxicity
patients
renal
impairment
use
nucynta
tablets
patients
severe
renal
impairment
recommended
due
accumulation
metabolite
formed
glucuronidation
tapentadol
clinical
relevance
elevated
metabolite
known
adverse
reactions
clinical
studies
common
adverse
reactions
nausea
dizziness
vomiting
somnolence
please
see
full
prescribing
information
including
boxed
warning
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
may
cases
use
terms
predicts
forecasts
believes
potential
proposed
continue
estimates
anticipates
expects
plans
intends
may
could
might
words
convey
uncertainty
future
events
outcomes
identify
statements
examples
statements
contained
press
release
include
among
others
statements
regarding
financial
guidance
xtampza
er
nucynta
franchise
revenues
total
operating
expenses
current
future
market
opportunities
products
assumptions
related
thereto
statements
subject
numerous
important
factors
risks
uncertainties
may
cause
actual
events
results
performance
achievements
differ
materially
company
current
expectations
management
expectations
therefore
statements
press
release
could
also
affected
risks
uncertainties
relating
number
factors
including
impact
pandemic
ability
conduct
business
reach
customers
supply
market
products
ability
commercialize
grow
sales
products
ability
manage
relationships
licensors
success
competing
products
become
available
ability
obtain
maintain
regulatory
approval
products
product
candidates
related
restrictions
limitations
warnings
label
approved
product
size
markets
products
product
candidates
ability
service
markets
ability
obtain
reimbursement
payor
contracts
products
rate
degree
market
acceptance
products
product
candidates
costs
commercialization
activities
including
marketing
sales
distribution
changing
market
conditions
products
outcome
patent
infringement
litigation
may
brought
us
including
litigation
purdue
pharma
teva
pharmaceuticals
usa
outcome
governmental
investigation
related
manufacture
marketing
sale
opioid
medications
ability
secure
adequate
supplies
active
pharmaceutical
ingredient
products
manufacture
adequate
supplies
commercially
saleable
inventory
ability
obtain
funding
operations
business
development
regulatory
developments
expectations
regarding
ability
obtain
maintain
sufficient
intellectual
property
protection
products
ability
comply
stringent
foreign
government
regulation
manufacture
pharmaceutical
products
including
drug
enforcement
agency
dea
compliance
customer
concentration
accuracy
estimates
regarding
expenses
revenue
capital
requirements
need
additional
financing
risks
described
heading
risk
factors
quarterly
report
form
quarter
ended
june
filings
sec
statements
make
press
release
speak
date
press
release
assume
obligation
update
statements
whether
result
new
information
future
events
otherwise
date
press
release
